In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for biotech.
In Q&A, Chien predicts mRNA cancer vaccine will reshape oncology and ‘raise all boats’
David L Ryan/Globe Staff
By Jason MastJune 29, 2026
General Assignment Reporter
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth
Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to…
Moderna still bullish on mRNA, Ipsen's acquisition of Kartos, and more biotech news from The Readout
As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. | As…
Moderna, nota a livello internazionale per il suo vaccino anti-Covid che salva vite: cosa sta facendo oggi? In studio con noi il…
Speaking at a WIRED event Tuesday, Moderna CEO Stéphane Bancel said he was “encouraged” by the company’s dialog with the FDA—but…
